Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Year's Meeting Held by 4 Drug Industry Organizations in Tokyo
January 19, 2004
- Brand Image Still Hinders Acceptance of GE Drugs: PJ, So-net M3 Survey
January 19, 2004
- FJPWA Petitions Korosho Regarding Joint Purchasing
January 12, 2004
- DIAGNOSTIC NEWS IN BRIEF
January 12, 2004
- Council Supports Inspection, Payment of Dispensing Bills by Insurers
January 12, 2004
- MEDICAL DEVICE NEWS IN BRIEF
January 12, 2004
- Monkasho Facing 4.5% Budget Cut in FY2004
January 12, 2004
- JACDS to Create Certification System for Kampo Advisors
January 12, 2004
- NEW PRODUCTS
January 12, 2004
- Semi-annual Business Results
January 12, 2004
- Korosho Starts General Review of Post-Marketing Safety Policies
January 12, 2004
- Funding for Disease Measures Up Slightly in Korosho's FY2004 Budget
January 12, 2004
- Safety and Efficacy of Pravastatin in GVHD Proven: J-HOCS Study
January 12, 2004
- Korosho Earmarks Budget to Standardize Drug Bar Coding
January 12, 2004
- Ain Pharmaciez: Strong Growth in Semiannual Sales, Profits
January 12, 2004
- METI Receives Initial Budget Allocation of \857.6 Bil.
January 12, 2004
- Nippon Kayaku Expects Major New Products after 2008: Mr Shimada
January 12, 2004
- Korosho Raises Attention to Toxic Epidermal Necrolysis due to Ticlopidine: Safety Info
January 12, 2004
- FPMAJ Is Eager to Take Measures to Prevent Medical Accidents
January 12, 2004
- Obesity in Men, Low Weight in Girls Increasing: Korosho Survey
January 12, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…